Expression and prognostic value of cytokeratin 19 fragment antigen 21-1 and squamous cell carcinoma antigen in cervical cancer patients with lung metastasis

Abstract

Objective To investigate expression of cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) and squamous cell carcinoma antigen (SCC-Ag) in cervical cancer patients with lung metastasis before treatment and their prognostic value. Methods The pretreatment serum expression levels of SCC-Ag and CYFRA21-1 of 72 cervical cancer patients with lung metastasis were measured. Survival rate analysis and Cox proportional hazard model were performed to evaluate the prognostic significance of two pretreatment variables. Results The media survival time (MST) of 72 patients was 14 months, and 38 (52.8 %) patients with pulmonary metastasis occurred in 1 year of treatment. The pretreatment serum SCC-Ag and CYFRA21-1 levels in the patients with tumor diameter over 4 cm or with squamous cell carcinoma were higher than those in the other patients (all P 3.3 mg/L) was higher than that in the negative group (13 months vs 19 months, P 1.5 mg/L) was also higher than that in the negative group (14 months vs 21 months, P < 0.05). The result of Cox regression analysis showed that the tumor diameter (OR = 11.6, P = 0.01), pretreatment serum SCC-Ag (OR = 4.2, P= 0.01) and CYFRA21-1 (OR = 8.2, P= 0.05) levels were independent prognostic factors of overall survival. Conclusion Pretreatment CYFRA 21-1 and SCC-Ag levels may be considered as useful prognostic indicators for cervical cancer patients with lung metastasis. Key words: Cervical neoplasms; Lung metastasis; Cytokeratin 19 fragment antigen 21-1; Squamous cell carcinoma antigen